SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective

Area of Science:

• Oncology
• Nuclear Medicine
• Radiotherapy

Background:

• Limited treatment options exist for iodine-refractory differentiated thyroid cancer.
• Current therapies for advanced thyroid cancer often involve significant toxicity.

Purpose of the Study:

• To investigate Selumetinib's efficacy in resensitizing advanced differentiated thyroid cancer to radioiodine therapy.
• To evaluate the dosimetric aspects of radioiodine therapy in this patient population.

Main Methods:

• The SELIMETRY trial involves administering Selumetinib to patients with iodine-refractory thyroid cancer.
• Serial I-123 SPECT/CT scans assess iodine uptake changes post-Selumetinib.
• Patients with sufficient uptake receive I-131 therapy, followed by post-therapy SPECT/CT scans for dosimetry.

Main Results:

• The study aims to determine if Selumetinib resensitizes lesions to radioiodine therapy.
• Dosimetric calculations will predict absorbed dose to target lesions.
• Standardized image data collection across multiple centers is being established.

Conclusions:

• This trial may lead to individualized and optimized therapy for advanced thyroid cancer.
• The established network for molecular radiotherapy dosimetry could facilitate future clinical trials.